6533b7d6fe1ef96bd12670af

RESEARCH PRODUCT

The use of pilocarpine in opioid-induced xerostomia

Sebastiano MercadanteL. CalderoneM. SapioAlessandra CasuccioPatrizia VillariRoberto SerrettaFabio Fulfaro

subject

MaleNarcoticsmedicine.medical_specialtyPalliative caremedicine.medical_treatmentAdministration OralPainMuscarinic AgonistsXerostomiaGastroenterologyMuscarinic Agonist03 medical and health sciences0302 clinical medicinestomatognathic system030502 gerontologyNeoplasmsInternal medicinemedicineHumansAdverse effectAgedChemotherapybusiness.industryPilocarpinefood and beveragesGeneral MedicineMiddle AgedDry mouthstomatognathic diseasesTreatment OutcomeAnesthesiology and Pain MedicineOpioidPilocarpineNarcotic030220 oncology & carcinogenesisAnesthesiaToxicityMorphineNeoplasmFemalemedicine.symptom0305 other medical sciencebusinessHumanmedicine.drug

description

Oral dryness can be a symptom of asystemic disease, an adverse effect of anticholin-ergic, antiadrenergic or cytotoxic drug treatment, orit can be due to local radiotherapy. Opioid use isstrongly associated with xerostomia, although themechanism for this remains unclear; in one studypatients receiving morphine were four times morelikely to have a dry mouth than patients taking otherdrugs known to cause xerostomia.

yearjournalcountryeditionlanguage
2001-02-28Palliative Medicine
https://doi.org/10.1191/026921600701536273